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Mononuclear phagocytes such as monocytes, tissue-specific macrophages and dendritic cells are 
primary actors in both innate and adaptive immunity. These professional phagocytes can be 
parasitized by intracellular bacteria, turning them from housekeepers to hiding places and favoring 
chronic and/or disseminated infection. One of the most infamous is the bacteria that cause 
tuberculosis (TB), which is the most pandemic and one of the deadliest diseases with one third of 
the world’s population infected, and an average of 1.8 million deaths/year worldwide. 
Here we demonstrate the effective targeting and intracellular delivery of antibiotics to infected 
macrophages both in vitro and in vivo, using pH sensitive nanoscopic polymersomes made of 
PMPC-PDPA block copolymer. Polymersomes showed the ability to significantly enhance the 
efficacy of the antibiotics killing Mycobacterium bovis, Mycobacterium tuberculosis and another 
established intracellular pathogen the Staphylococcus aureus. Moreover, they demonstrated to 
easily access TB-like granuloma tissues - one of the harshest environments to penetrate - in 
zebrafish models. We thus successfully exploited this targeting for the effective eradication of 
several intracellular bacteria, including the M. tuberculosis - the etiological agent of human TB. 
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The human innate immune system - our frontline defense against potential pathogens - includes a 
range of effector cells.1 Examples are professional phagocytes, such as granulocytes (i.e. basophils, 
eosinophils and neutrophils) and mononuclear phagocytes (macrophages, dendritic cells, and 
monocytes). Phagocytes are responsible for the clearance of bacterial pathogens from the host and 
have attracted much interest in the context of focused antimicrobial drug delivery. In parallel, some 
of the deadliest pathogens have acquired the ability to evade the phagocytes’ unique panel of 
molecular defenses. While phagocytes have evolved to eradicate invading pathogens, few selected 
bacteria have evolved strategies to make macrophages as their preferential niche evading host 
killing. Such a strategy is known as the ‘macrophage paradox’ and it is the product of millions of 
years of co-evolution.2,3 Pathogens may inhabit different compartments in the macrophage. Listeria 
monocytogenes, Shigella flexneri and the Rickettsiae rickettsii proliferate within the macrophage 
cytosol,4 Listeria pneumophila colonizes the ER-like vacuoles,5 and Salmonella enterica exploits 
the late endosomal compartments.6 More recently, a similar strategy has been reported for 
Staphylococcus aureus, suggesting that these bacteria are capable of hiding within professional 
phagocytes.7,8 The most studied intracellular pathogen Mycobacterium tuberculosis, survives 
within macrophage phagosomes otherwise a detrimental environment for most pathogens.9,10 Yet, 
M. tuberculosis has evolved creating proteins that hinder phagosome maturation preventing its 
fusion with lysosomes.9,11 The first-line therapy against TB includes an antibiotic combination 
regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol for long time (six to nine months). 
Such duration of the therapies promoted a dramatic rise in multidrug-resistant (MDR)-TB, despite 
the recent approval of the bedaquiline as new approach for MDR-TB treatment.12,13 Also, 
antibacterial drugs have been demonstrated to accumulate within specific compartments of host 
cells, like the bedaquiline which is stored in host lipid droplets.14 These seems to act as an antibiotic 
reservoir that could be transferred to bacteria during host lipid consumption.15,16 It is evident that a 
way to improve drug efficacy is to encapsulate the active agent into a carrier that delivers it into the 
infected cell. Also, the optimal drug delivery systems should incorporate targeting specificity for 
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the host cells type and should be able to cross biological barriers with the aim to finally reach the 
intracellular niche where the microorganisms hide - even more critical today with the emergence 
of drug resistant strains. 
We propose here the use of synthetic vesicles, known as polymersomes,17 that can target infected 
phagocytes, to reach intracellular pathogens in their sub-cellular compartment, and to locally 
release their antibacterial cargo. These polymersomes are formed through the self-assembly of 
amphiphilic copolymers in aqueous media and combine the advantages of long-term stability with 
the potential to encapsulate a broad range compounds (or cargos).18–22 The pH-sensitive block 
copolymer poly(2-(methacryloyloxy) ethyl-phosphorylcholine)-co-poly(2-
(diisopropylamino)ethyl methacrylate) (PMPC-PDPA) can combine specific cellular targeting in 
non-professional phagocytic cells (through the PMPC affinity toward the scavenger receptor B1),23 
with effective endosomal and cytosolic drug delivery following internalization (by the pH sensitive 
PDPA).21,24–27  
In this work, we explored the dynamics of the cellular uptake of PMPC-PDPA polymersomes in 
professional phagocytes, and their intracellular trafficking. As in vivo model for polymersomes 
distribution and accumulation, we chose the transparent zebrafish embryo infected with 
Mycobacterium marinum.28 In this system, the availability of specific cell lines allows real-time 
imaging of nanoparticles with the cell of interest such as leucocytes. Here, we described the ability 
of polymersomes to efficiently target macrophages in vivo, and to co-localize with their intracellular 
pathogens. We made further experiments in zebrafish that had developed granulomas, the hallmark 
of tuberculosis,28,29 and showed that polymersomes penetrate such environment, which is hard to 
access.30,31 These evidences led us to investigate the potential of antimicrobial-loaded 
polymersomes for intracellular pathogens clearance, both in vitro and in vivo. We demonstrated 
that PMPC-PDPA polymersomes, loaded with anti-mycobacterial drugs (gentamicin, lysostaphin, 
vancomycin, rifampicin, and isoniazid), are able to decrease, and in some cases even eradicate, 
intracellular S. aureus, M. bovis-attenuated Bacillus Calmette–Guérin (BCG), M. Marinum and M. 
tuberculosis. 
 
Results and discussion 
 
Polymersomes drug release profile and internalization dynamics in human macrophages. 
The selective targeting of specific immune cells sub-populations represents a new paradigm in 
precise nanomedicine and will have huge impact in fields like cancer immunotherapies or 
infectious diseases. We explored in this work the possibility of targeting the immune system and 
studied how polymersomes can be used to deliver drugs for the treatment of intracellular 
pathogens, which are more difficult to eradicate compared to extracellular bacteria. 
To do this, we synthesized PMPC-PDPA copolymers using atom transfer radical polymerization 
(ATRP), and fully characterized the products of the reaction by gel permeation chromatography 
(GPC) (Figure S1a) and NMR spectroscopy (Figure S1b). PMPC-PDPA was also functionalized 
with Cy5 dye by click reaction to produce fluorescent polymers. Then, we used the film hydration 
method to induce the self-assemble of the PMPC-PDPA copolymers into vesicles of about 100 nm. 
It is worth mentioning that film hydration usually induces the formation of differently shaped 
nanostructures. We thus isolated monodisperse spherical polymersomes by means of density 
gradient centrifugation.32 Transmission electron microscopy (TEM) confirmed the purification 
processes were successful in isolating spherical polymersomes with homogeneous shape 
distributions (Figure Sc1 and Sc2). The encapsulation of drugs did not affect polymersomes shape 
(Figure Sd1 and Sd2) nor changed their size distribution (Figure S1f). Also, the polymer 
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functionalization with Cy5 was confirmed to be stable under harsh acidic condition (pH 2), a crucial 
aspect for correct cell uptake quantifications (Figure S1e). We then studied the drug release profile 
of pH sensitive PMPC-PDPA polymersomes during time. Free- and rifampicin-loaded 
polymersomes have been placed in a dialysis bag under stirring (see materials and methods section 
for details). Rifampicin-loaded polymersomes do not release the drug at physiological pH (pH 7.4), 
confirming the high stability in circulation-like conditions (Figure S2, pink line). The drop in pH 
(pH 6) triggers a steady release of the encapsulated drug (Figure S2, red line). Conversely, there is 
no control over free (non-encapsulated) rifampicin distribution, which just follows its gradient 
concentration equilibrium (Figure S2, blue and cyan lines). This is a quite important outcome, as 
polymersomes release the drug only upon internalization in the cells and avoid undesired drug 
distribution in other body compartments. At the same time, the slow polymersomes-driven release 
(c.a. 20% of the initial dose) makes them a powerful drug reservoir that is constantly and steadily 
released in the cells for long times. 
We then studied the kinetics of PMPC-PDPA polymersomes internalization in vitro in macrophages 
using the monocytes-derived macrophages THP-1. Live cell confocal laser scanning microscopy 
(CLSM) imaging of macrophages stained by CellMaskTM shows that the uptake of PMPC-PDPA 
polymersomes occurs within minutes post-exposure (Figure 1a). We observed full saturation of the 
membrane within minutes after incubation, with several internalization events occurring few 
seconds after the initial contact of the polymersomes with the plasma membrane. The kinetic plots 
of uptake for four regions of interest (ROI) confirm rapid binding and endocytosis with very little 
difference between the plasma membrane or cytosolic ROIs (Figure 1b). Representative confocal 
3D scans (Figure 1c) show the presence of the polymersomes within the entire volume of the 
macrophages. We then addressed the intracellular trafficking of polymersomes. It is important 
mentioning that THP-1 macrophages are challenging to be transfected with external genetic 
materials. Hence, it is very difficult to create chimera proteins (e.g., GFP-fusion) with the aim to 
carry out live cell imaging of (marked) intracellular organelles, and their possible co-localization 
with polymersomes. For THP-1, the two possible options are thus post-fixation methods like 
immunofluorescence or live imaging based on chemical staining (e.g., lysotracker). Cy5-labelled 
polymersomes have been incubated with macrophages for a short period of time (30 minutes). 
Immunofluorescence analyses (Figure 1d) show no co-localization signal between the Cy5-
polymers and the early endosome antigen 1 EEA1 (which marks the early endosomes). Similar 
results were observed during live-cell imaging, where THP-1 cells were first incubated with Cy5-
polymersomes again for 30 minutes and then stained with LysoTracker (for marking all the acidic 
compartments). The lack of co-localization suggest that the Cy5-polymers diffuse out of the 
endocytic pathways. We then speculated that the slow sustained PMPC-PDPA drug release (Figure 
S2) could induce accumulation of polymersomes in later stages of endocytosis as a function of both 
(high) concentration of polymersomes and incubation time. We tested this hypothesis and 
confirmed that Cy5-polymers accumulate in the lysosomal compartments after very long incubation 
time (24 and 72 hours, Figure S3a-b). The question of timing is indeed an important aspect to boost 
the amount of drug in the compartments where bacteria hide and proliferate. We also CLSM-
imaged and quantified the presence of polymersomes at 8, 24 and 72 hours of incubation time 
(Figure S4a). Calcein (green) staining further validated the efficient uptake and intracellular 
distribution of polymersomes by macrophages, which remained viable for the incubation time 
tested. We further quantified the uptake using high performance liquid chromatography (HPLC) of 
the cell lysates after different incubation times. HPLC-based uptake quantifications revealed about 
104 polymersomes/cell after 8 hours, the number of polymersomes rose by 3 ⋅ 104 after 24h and 
this remained constant up to 72 hours of incubation (Figure S4b). 
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Figure 1. PMPC polymersomes interaction with phagocytes in vitro. (a) Real-time imaging of 
polymersomes entering monocyte-derived macrophages (THP-1 cells) using confocal laser 
scanning microscopy (CLSM). Note the polymersomes (red signal) are labelled using Cy5, and the 
macrophage membrane (green signal) is stained using CellMaskTM. (b) Polymersomes uptake 
measured in 4 different regions of interest (ROI) in (a) plotted as a function of time. (c) Confocal 
3D scan of THP-1 cells incubated with Cy5 polymersomes. (d) Immunofluorescence analyses 
showing no co-localization between polymersomes (red) and EEA1 (green). (e) Live cell imaging 
of polymersomes (red) and LysoTracker-stained (green) cells. (f) Polymersomes uptake after 
inhibition of different cellular components: CytochalasinB (actin inhibitor), Dynasore (dynamin 
inhibitor), Fucoidan (Scavenger Receptors A and B inhibitor), and Polyinosinic acid (Scavenger 
Receptor A inhibitor and Toll-like 3 receptor agonist ligand stimulator). (t-test comparison with 
*𝑝 < 0.05). 
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We then investigated the driving force for polymersomes internalization and studied the receptors 
involved in their uptake. To investigate this, macrophages were incubated with the actin inhibitor 
cytochalasinB. We observed a complete inhibition of polymersomes uptake, confirming that the 
entry process is mediated by actin-dependent transport (Figure 1f). Moreover, incubation with 
15𝜇M and 30𝜇M dynasore (a dynamin inhibitor) reduced the polymersomes uptake by 40% and 
60%, respectively, but did not stop it completely (Figure 1f). The GTPase dynamin regulates 
membrane fission in clathrin-mediated endocytosis, as well as in phago- and macropinocytosis in 
eukaryotic cells.33 Few dynamin-independent entry pathways have been described, and they include 
the CDC42 (the preferred entry route of cholera toxin B),34 ARF1 and ARF6,35,36 and Flotillin 1 
and 2 pathways.37,38 The polymersomes uptake in the presence of dynasore suggest that they can 
gain access through dynamin-independent endocytosis. Scavenger Receptors (SR) and SR-B1 in 
particular, are known receptors for PMPC-PDPA polymersomes uptake in non-professional 
phagocytes.23 SR-B1 is known to play an critical role in pathogens recognition and in cholesterol 
homoeostasis.39–41 To test whether macrophages also internalize polymersomes using scavenger 
receptors, we incubated the cells with fucoidan, an inhibitor of Scavenger Receptors class A and B 
(SR-A and B). Despite the presence of the inhibitor, polymersomes were able also in this case to 
access macrophages, albeit with a considerable decrease in uptake of about 40% (Figure 1f). In 
order to define the contribution of the class A or B, macrophages were treated with polyinosinic 
acid (PA), a selective inhibitor of SR-A. Surprisingly, PA led to a significant increase in 
polymersomes uptake (Figure 2b), even though this can be explained by the fact that PA can 
improve uptake activities by binding to Toll-like receptor 3.42 The inhibition studies, albeit not 
conclusive about the exact endocytic process involved, suggest that polymersomes uptake is a 
complex orchestra of multiple pathways. 
 
Polymersomes are safe delivery agents 
Even though many polymersomes were internalized by the macrophages, viability assays (MTT) 
confirmed that free- and antimicrobial-encapsulated polymersomes do not affect the metabolic 
activity of THP-1 cells for concentrations up to 1 mg/mL (Figure 2a). To provide a broader 
overview of potential change in cell metabolism, we investigated the expression of specific stress-
related genes upon polymersomes incubation. We quantified the expression profiles of the (i) p21 
and p53 genes, key regulators of cell cycle and apoptosis, of the (ii) superoxide dismutase (SOD) 
and catalase (CAT) to check for potential O2 radicals-induced oxidative stress (likely to occur in 
macrophages), and of the (iii) detoxification-related cytochromes CYP1Aq and CYP1B1. We also 
quantified the expression levels of ATF4 and ATF6, which are the sensors of the unfolded protein 
response pathway (UPR). UPR is an adaptive cellular program used by eukaryotic cells to cope 
with protein misfolding stress. We thus covered a broad panel of stress-related pathways and did 
not detect any significant differential regulations of genes between untreated- and polymersomes-
treated macrophages (Figure 2b). We confirmed that high amount of polymersomes (1 mg/mL) did 
not trigger any inflammation in macrophages as well. This has been validated by 
immunofluorescence analyses, where the localization of the transcription factor nuclear factor κB 
(Nf-κB) has been assessed (Figure 2c-f). It is indeed established that in non-inflamed conditions, 
the majority of the Nf-κB is localized within the cytosol, while higher nuclear presence of Nf-κB 
indicates that macrophages are triggering inflammation. Being a transcription factor, the Nf-κB 
promote the expression of a whole panel of pro-inflammatory cytokines that regulate the 
inflammation process. Our data show that macrophages treated with polymersomes (Figure 2d) 
have the same nuclear presence of Nf-κB of untreated cells (Figure 2c), while lipopolysaccharide 
(LPS)-treated macrophages have a significantly higher nuclear presence of the transcription factor 
(Figure 2e). The co-localization quantification (Figure 2f) confirms the safety of polymersomes. 
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Figure 2. Polymersomes biocompatibility. (a) Viability assays (MTT) of THP-1 cells incubated 
with un-loaded and with antibiotic-loaded (rifampicin, isoniazid, and combination of both) 
polymersomes. Ctrl-: Cells treated with PBS; Ctrl+; DMSO 5%; [polymersomes]: 1 mg/mL; [RIF]: 
30 𝜇g/mL; [isoniazid]: 3 𝜇g/mL. (b) Quantitative PCR (qPCR) for analyzing the expression levels 
of genes involved in cell proliferation (p21 and p53), cell stress (CYP1A1 and CYP1B1), Unfolded 
Protein Response (ATF4 and ATF6), and oxidative stress (CAT and SOD). (c-e) Representative 
immunofluorescence imaging to assess Nf-κb-based inflammation in untreated- (c), polymersomes-
treated (d), and LPS-treated (e) macrophages. Red: Nf-κb, blue: nucleus. (f) Co-localization 
quantification of the images in (c-e) using the Pearson's correlation coefficient. 
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Biodistribution of polymersomes in zebrafish 
We moved to a relevant in vivo model and chose the Danio rerio (zebrafish) embryo. These animals 
are optically transparent, allowing observation of polymersomes targeting and delivery over time 
in the same animal. The availability of fluorescent transgenic lines labelling immune cell 
populations allows imaging of macrophages and neutrophils.43 Furthermore, there are well-
established zebrafish models of human-relevant infections of S. aureus,44,45 and M. marinum (a 
close relative of human TB complex, and a natural pathogen of fish species).46–50 In order to 
evaluate the potential of the polymersomes to target intracellular pathogens we tested the 
nanoparticles in zebrafish infected with M. marinum, the causative agent of tuberculosis in 
ectotherms and a close relative of M. tuberculosis. For this, about 200 mycobacteria expressing 
GFP were injected intravenously (blood infection) at day 2 post fertilization in the recombinant line 
of zebrafish Tg (mpeg1:mcherry), which has macrophages fluorescently labelled (Figure 3a). After 
24 hours, we injected Cy5 labelled polymersomes and monitored their uptake by macrophages as a 
function of time. Polymersomes could be observed within the target cells already 10 minutes after 
injection, and their intracellular uptake increased over the following 24 hours (Figure 3b). At 8 
hours post injection, polymersomes clearly aggregated into macrophages already infected with M. 
marinum (Figure 3a, c and d). Supporting Video 1 and Figure S7 show in detail the intracellular 
localization within macrophages of both polymersomes and M. marinum. We quantified the caudal 
region of 3 zebrafish larvae and observed polymersomes within 93% of their intended targets (40 
out of 43 M. marinum-infected macrophages). Qualitative images also show that polymersomes are 
taken up by infected macrophages already at 10 minutes and persist up to three days in individually 
infected macrophages (Fig S5a-d). Moreover, polymersomes were seen surrounding and then 
penetrating not only individual macrophages but also the first macrophage aggregates (early 
granulomas) that form by three-day post infection (Figure Sd1-d3). At the same time, neutrophils 
were not targeted by the same polymersomes, demonstrating a high level of selectivity towards 
macrophages only (Figure S6). Similar results were obtained when the infecting agent of zebrafish 
was S. aureus (Figure S5e,f). In this case, fluorescent lysostaphin delivered by polymersomes into 
infected phagocytes co-localized with intracellular S. aureus (Figure S5f). To evaluate if 
polymersomes can enter bigger granulomas, we employed a different model of M. marinum where 
the pathogen is injected directly into the neural tube of the zebrafish at day 3 post birth (Figure 3e). 
This type of infection promotes the formation of large granulomas made of hundreds of cells, a 
hallmark of tuberculosis disease. Polymersomes injected intravenously at day 4 post infection 
clearly localize within the granuloma after 8 hours (Fig 3e-g and Supporting Video 2). Image 
analysis confirmed that polymersomes quickly accumulated within the granulomas during the first 
hour post administration and continued to further concentrate, albeit slower, over time (Figure 3h). 
This new zebrafish neural tube infection model developed here has the advantage of possessing 
some of the characteristics missing in the mouse granulomas, which are present in human TB. These 
features are local necrosis, vascular thrombosis, cavity formation and hypoxia.51 Also, there are 
evidence that zebrafish can be efficiently used to predict the circulation of nanoparticles in mice. It 
thus represents a valid alternative to mammalian models for pre-clinical screenings.52 
 
Efficacy of polymersomes in eradicating intracellular bacteria 
After assessing the polymersomes distribution at cellular level and in zebrafish, we moved on 
addressing their efficacy in reducing bacterial burden in infected cells. We used the model 
intracellular pathogens S. aureus, M.bovis-BCG, M. tuberculosis, and M. marinum. First, we 
confirmed that polymersomes can effectively load vancomycin, gentamicin, lysostaphin, 
rifampicin and isoniazid (Figure 4a). To this respect, it is important to mention that the different 
drugs have considerable differences in molecular mass, hydrophilicity, and mechanism of action. 
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Figure 3. Polymersomes accumulation in macrophages and granulomas in zebrafish 
embryos infected with M. marinum. (a). A zebrafish embryo fluorescently labelled with 
macrophages (red) injected intravenously with M. marinum and the following day with 
polymersomes containing Cy5 (white). The image was taken 8 hours after polymersomes 
injection. H, head region; Y, Yolk sac. (b) Quantification of polymersomes uptake over-time in 
macrophages in zebrafish larvae. (c) enlarged area in (a) where polymersomes are detected 
within infected macrophages (blue arrows). DLAV, Dorsal longitudinal anastomotic vessel. 
ISV, intersegmental vessel; CA, Caudal Artery; CV, Caudal Vein. (d) enlarged area in (c) where 
macrophages containing M. marinum and polymersomes are evident (blue arrows). (e) Zebrafish 
embryos fluorescently labelled with endothelial cells (green) were injected with M. marinum 
(red) in the neural tube. Four days later, polymersomes containing Cy5 (white) were injected 
intravenously and the whole zebrafish was imaged eight hours later. H, Head region; Y, Yolk 
sac. (f) shows the image in (e) without the signal of green endothelial cells and red M. marinum 
in order to better observe the selective accumulation of polymersomes (blue arrows) in the 
granuloma region. The yellow box in (e) is seen enlarged in (g) for observing details of 
polymersomes accumulation in the granuloma. DLAV, Dorsal Longitudinal Anastomotic 
Vessel; DA, Dorsal Aorta; PCV, Posterior Cardinal Vein. A graph showing accumulation over 
time of polymersomes in neural tube granulomas is shown in (h). Scale bars: (a), 300 µm; (c) 
100 µm, (d) 25 µm. (e), 300 µm, (f), 300 µm, (g), 50 µm. 
10 
Lysostaphin is a 27 KDa glycylglycine endopeptidase only soluble in water acting on the S. aureus 
cell walls. Gentamicin is a highly hydrophilic aminoglycoside that binds to the 30S subunit of the 
bacterial ribosome. Vancomycin is a relatively hydrophilic glycosylated non ribosomal peptide 
that inhibits cell wall synthesis. Rifampicin is a hydrophobic heterocyclic modified 
naphthoquinone that inhibits bacterial DNA-dependent RNA synthesis. Isoniazid is a small 
synthetic derivative of nicotinic acid with a poor water solubility that upon enzymatic activation 
inhibits the synthesis of mycoloic acids. These drugs are used clinically for the treatment of several 
infections and make a very diverse population of molecules to test the versatility of polymersomes. 
We tested the effect of the antimicrobials in the treatment of different infections by measuring the 
colony forming units (CFUs) after increasing incubation periods. Treatment with polymersomes 
loaded with rifampicin or gentamicin improved the drug efficacy and reduced the number of viable 
S. aureus in THP-1 cells compared with controls (Figure 4b). Encapsulation of lysostaphin or 
vancomycin within polymersomes did not significantly improve or hinder drug efficacy. For both 
BTG and M. tuberculosis, we limited our screening to rifampicin and isoniazid either alone or in 
combination mirroring the most common therapeutic approach used for the treatment of 
tuberculosis. With respect to BCG infection, no significant differences were observed in CFUs 
after 1 day of treatment (Figure 4c). Only the free rifampicin was able to reduce the bacterial 
colonies. However, a significant difference was observed after 72 hours of treatment, where both 
rifampicin and isoniazid-encapsulated polymersomes elicited a clear reduction in bacteria 
compared to the free drug (Figure 4c). Notably, the rifampicin/isoniazid co-loaded polymersomes 
completely eradicated the intracellular BCG after 72 hours (no CFUs detected). Similar results 
were observed with M. tuberculosis infected THP-1 cells (Figure 4d). In this case, after 24 hours 
of treatment, the multiple drug co-loaded polymersomes significantly reduced bacterial burden 
compared to the controls. Moreover, this drug formulation was also able to eradicate intracellular 
M. tuberculosis after 72 hours of treatment (Figure 4d). The intracellular CFUs are very-well 
known to normally rise inside host macrophages if no antimicrobials are inoculated.53,54 It is 
important mentioning that an improvement in polymersomes-mediated delivery was not detected 
only upon using lysostaphin (against S. aureus) and isoniazid (against M. tuberculosis). Two 
possible hypotheses can be inferred to explain this behavior. First, the drug mechanism of action 
can be altered by the cytosolic environment. Second, both endo-lysosomal and cytosolic-resident 
bacteria are targeted. This can have significant different outcomes depending on the specific drug 
used. For example, while there was not any improvement for isoniazid treating M. tuberculosis, a 
one log improvement was observed for isoniazid treating M. bovis. This suggests that M. 
tuberculosis is more efficient in escaping into the cytosol.55 Also, isoniazid may act better within 
endo-lysosomal compartment rather than within the cytosol. Most importantly, the combination 
isoniazid/rifampicin is the most successful with full sterilization in M. tuberculosis infected 
macrophage. 
We finally validate the therapeutic impact also in zebrafish and tested the ability of polymersomes 
encapsulated antibiotics to reduce bacterial burden in vivo. Zebrafish embryos were infected with 
mCherry-expressing M. marinum, and with GFP expressing S. aureus. In the S. aureus infection 
model, zebrafish received an injection of 1200 CFU, at which dose the infection is either cleared or 
leads to rapid death of the fish. Zebrafish begin to succumb to the infection after approximately 40 
hours post infection, so this time-point was used as an output to determine the extent of zebrafish 
infection. To compare the effect of encapsulated antimicrobials and free antimicrobials to treat S. 
aureus infection, zebrafish embryos were injected with S. aureus followed by a second injection of 
drug loaded polymersomes 20 hours later. We assessed the efficacy of the four drugs tested in vitro, 
lysostaphin, vancomycin, gentamicin and rifampicin (Figures 5a-b). In agreement with the in vitro 
results, only encapsulated rifampicin and gentamicin treatment improved the outcome of infection.  
11 
 
Figure 4. Polymersomes eradicating intracellular pathogens in human macrophages. (a) 
Average number of drug per single polymersome measured by HPLC (b) THP-1 macrophages 
infected with S. aureus (M.O.I of 5:1) for 6 hours. Following infection, gentamicin was added to 
the media to kill extra-cellular bacteria. Macrophages were subsequently treated with 
polymersomes encapsulating gentamicin, rifampicin, vancomycin, or lysostaphin (all at 1𝜇g/mL). 
At 6, 22, and 46 hours macrophages were lysed and plated on a BHI agar plate for bacterial 
colonies to be counted (One-way ANOVA **฀ < 0.01, ***฀ < 0.001, error bars = SEM, n = 3). 
Viability (CFU) analyses of BCG (c), and (d) M. tuberculosis after 24 and 72 hours of incubation 
with the different formulations (One-way ANOVA with *฀ < 0.05and **฀ < 0.01). 
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Lysostaphin and vancomycin did not change the outcome of infection, with similar numbers to the 
control groups showing high numbers of bacteria (Figure 5a). The polymersomes-encapsulated 
rifampicin was the most effective treatment, resulting in a reduction in the bacterial CFUs and 
preventing the fish from succumbing to overwhelming infections. Polymersomes did improve 
considerably the output with the rifampicin formulation getting very low CFUs and with survival 
close to 100%. The efficacy of polymersomes delivered rifampicin was confirmed using a second 
in vivo model, the M. marinum infected zebrafish model of TB. In this case, mCherry-expressing 
fluorescent bacteria were microinjected, and 24 hours later an injection of the polymersomes-
encapsulated drugs (or controls) was performed. As was the case for S. aureus infected zebrafish, 
rifampicin-encapsulated polymersomes significantly reduced the M. marinum burden in vivo, 
compared to the same concentration of free drug (Figures 5b). The data on zebrafish point out two 
main questions. First, there is a good matching between the in vitro and in vivo assays, which is a 
fundamental validation of the data. Second, we confirmed that much lower doses of drugs are 
required to reach a therapeutic concentration inside the cells when the antimicrobials drugs are 







Finding alternative and more effective solutions to bacterial infections is becoming increasingly 
important with the rise of antimicrobial resistant bacteria rendering many therapies ineffective. In 
addition, serious diseases like TB require long-term treatments, which usually need doses of a 
combination of antibiotics for long periods (at least six months), with a consequent rise of serious 
side effects, and bacterial resistance. New therapies, which can selectively target only infected 
Figure 5. Enhanced efficacy of antimicrobials in vivo upon encapsulation in polymersomes. 
(a) Zebrafish embryos 2 days post infection were injected with S. aureus (data time 0) followed by 
a second injection 20 hours later with either PBS, empty polymersomes, free drug and 
polymersomes loaded with lysostaphin, vancomycin, gentamicin, and rifampicin. Zebrafish were 
then left for 20 hours before being homogenized and plated on BHI agar for viable colony counts. 
Graphs show the total number of CFU after treatment (Kruskal-Wallis test with Dunn’s multiple 
comparison *p <0.05, **p <0.01 and ***p <0.001). (b) Quantification of mCherry expressing M. 
marinum bacterial burden in zebrafish embryos treated with empty polymersomes, free drugs, and 
polymersomes loaded with rifampicin, isoniazid, and their combination. (ANOVA test comparison 
with *p < 0.05).  
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phagocytes, are nowadays required in order to improve the efficacy while limiting off target side 
effects. In this work, we have demonstrated that PMPC-PDPA polymersomes can be loaded with a 
large variety of antibiotics, including proteins (lysostaphin), small peptides (vancomycin), glycols 
(gentamicin), poorly water-soluble organics such as quinones (rifampicin) and functionalised 
pyridines (Isoniazid), thus covering a large repertoire of possible chemistries. We have shown that 
polymersomes can deliver antibiotics to treat intracellular pathogen-related infections, and to 
potentially decrease the dose and duration of treatment required for bacterial eradication. Both in 
vitro in human cells and in vivo experiments demonstrated that these nanoscopic synthetic vesicles 
were internalised by macrophages, without inducing toxicity, and were able to escape the endocytic 
pathway. We have demonstrated that drug-encapsulated polymersomes were able to reduce S. 
aureus, BCG, M. tuberculosis, and M. marinum bacterial burden, again using in vitro and in vivo 
approaches. Antimicrobial-loaded polymersomes were more effective compared with the same 
concentration of free drug, and in some cases were able to eradicate the intracellular 
microorganisms completely. We thus believe this technology can be exploited to reduce the 
effective dose required for therapy, with a consequent potential reduction in antimicrobial 
resistance. In addition, encapsulation of antimicrobials could help completely eradicate infection 





Materials and Methods 
 
PMPC-PDPA copolymer synthesis. In a typical ATRP procedure, a 100 mL round bottom flask 
equipped with a magnetic stir bar and a rubber septum was loaded with 2-methacryloyloxyethyl 
phosphorylcholine (MPC, 5 g, 16.9 mmol), 2-(4-morpholino)ethyl 2-bromoisobutyrate (ME-Br) 
initiator (189 mg, 0.7 mmol) and 6 mL ethanol, and this solution was deoxygenated by purging N2 
for 1 h under stirring at room temperature. Then, 2,2’-bipyridine (bpy) ligand (212 mg, 1.4 mmol) 
and Cu(I)Br (97 mg, 0.7 mmol) were added as solids whilst maintaining the flask under a mild 
positive N2 pressure. The [MPC]:[ME-Br]:[CuBr]:[bpy] relative molar ratios were 25:1:1:2. The 
reaction was carried out under a N2 atmosphere at 30 °C. After 90 minutes, a solution of 
2(diisopropylamino)ethyl methacrylate (DPA, 12.3 g, 57.6 mmol) in ethanol (15 mL), previously 
deoxygenated by purging N2 for 1 h at room temperature, was injected into the flask. After 48 h, 
the reaction solution was opened to the air, diluted by addition of ethanol (≈200 mL) and left stirring 
for 1 h. The solution was then passed through a silica column to remove the copper catalyst. After 
this step, the filtrate was concentrated by rotary evaporation and dialyzed using a 1 kDa MWCO 
dialysis membrane (Spectrum Labs, Netherland) against chloroform/methanol 2:1 (v/v) (2 × 500 
mL), methanol (2 × 500 mL), and double-distilled water (4 × 2 L). At least 8 h passed between 
changes. After dialysis the copolymer was isolated by freeze-drying and characterized by 1H-NMR 
spectroscopy performed on an Avance III 600 spectrometer from Bruker (Billerica, USA), and gel 
permeation chromatography performed on a GPCMax equipped with an RI detector from Malvern 
Technologies (Greater Malvern, UK) with acidic water (0.25 vol% TFA in water) as solvent on a 
Novamax column (including guard column) from PSS Polymers (Mainz, Germany). 
 
Polymersomes production and characterization. PMPC-PDPA self-assembly of polymersomes, 
as well as drugs encapsulation, was carried out using the thin film rehydration method. In particular, 
the polymers was first dissolved in a chloroform:methanol solution (2:1), containing also the 
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antibiotics (rifampicin, isoniazid, gentamicin, and lysostaphin) at 1 mg/mL each. For the production 
of rhodamine-labeled polymersomes, Rhodamine 6B octadecylester (Sigma) was used (with a 5% 
molar ratio with the polymer). The solvent was then evaporated, and the film was rehydrated with 
endotoxin/LPS-free Dulbecco’s PBS (Sigma) for a period of 4 weeks under vigorous stirring, in 
order to have a final polymer concentration of 10 mg/mL. After this period, the formed 
polymersomes were purified from the formed tubular structures and only spherical nanoparticles 
were isolated, according to sucrose-based density gradient centrifugation.32 This pre-purified 
samples were then further purified by size exclusion chromatography for isolating the antibiotics-
encapsulated nano-vesicles and removing the free drugs. This purified solution was then analyzed 
by TEM, performed using a FEI Tecnai G2 Spirit electron microscope and/or a JEOL 2100 
operating at 200 kV equipped with a CCD camera Orius SC2001 from Gatan. Copper grids were 
glow discharged and the sample was adsorbed onto the grid. The sample was then stained with 
0.75wt% phosphotungstic acid (PTA) adjusted to pH 7.4 with NaOH. All the TEM analyses were 
carried out with dried samples. DLS analyses (for characterizing the nanoparticles size distribution) 
were carried out using a Zetasizer Nano ZS (Malvern Ltd.) at a copolymer concentration of 0.25 
mg/mL. DLS measurements were based on 12−14 runs, 10-second sub-runs. Samples were 
analyzed at 25°C with a scattering angle of 173° and a 633 nm HeNe laser based on a material 
refractive index (RI) of 1.59, a dispersant refractive index of 1.330 and a viscosity of 0.89. Drugs 
encapsulation was measured by reverse-phase - HPLC measurements. This was performed with 
Dionex Ultimate 3000 instrument equipped with Variable Wavelength Detector (VWD) to analyze 
the UV absorption of the polymers at 220 nm and the enzymes signal at 280 nm. A gradient of 
H2O+Tryfluoroacetic acid 0.05% (TFA) (A) and MeOH + TFA 0.05% (B) from 0 min (5%B) to 
30 min (100%B) was used to run the samples trough a C18 column (Phenomenex). The peak area 
was integrated by using Chomeleon version 6.8. 
 
Cell culture, in vitro uptake, NF-κB signaling and trafficking studies. Human monocytes (THP-
1 cell lines) were differentiated to macrophages through incubation with 5 ng/mL of phorbol 12-
myristate 13-acetate (PMA, Sigma) for 48 hours on 24/96 well plates for cell viability/uptake 
quantification respectively, and on µ-Slide 8 well glass-bottom dishes (ibidi) for confocal analyses. 
We chose this PMA concentration as it has been found to not undesirable regulate genes 
expression.15 For cell viability, the Thiazolyl Blue Tetrazolium Blue (MTT, Sigma) method was 
used. Briefly, cells were seeded at a concentration of 5 ⋅ 103 cells/well in a 96 well plate overnight 
(O.N.). Increasing concentrations of polymersomes were then added in the growth media, namely 
0.1, 0.5, and 1 mg/mL, for periods of 24, 48, and 72 hours. The medium growth was then removed, 
and an acidified solution of isopropanol was added to dissolve the water insoluble MTT formazan. 
The solubilized blue crystals were measured colorimetrically at 570 nm (plate reader ELx800, 
BioTek). Viability assays were also carried out incubating cells with 10 ฀M Acetoxymethyl (AM) 
Calcein staining (Invitrogen) for 1 hour, followed by confocal microscopy analyses (Leica TCS 
SP8). For uptake quantification, THP-1 cells were incubated with rhodamine-labeled 
polymersomes (0.1 mg/mL) for 8, 24, and 72 hours, followed by 3 steps of PBS washing and SDS-
based cell lysis. Cell debris were then removed by centrifugation, and the rhodamine-polymers 
present in the supernatant quantified by HPLC. 
NF-κB signaling imaging was preformed using CLSM. Firstly, THP-1 cells were seeded at a 
concentration of 5×103 cells per µ-Slide 8 well glass-bottom dishes (ibidi) and differentiated as 
above mentioned. Differentiated macrophages were either untreated (CTRL) or incubated with 
PMPC–PDPA polymersomes (1 mg/mL), and LPS (10 ng/mL, CTRL+) for 24 h in a humidified 
atmosphere, 95% air, 5% CO2 at 37 
◦C. Following treatment, cells were washed with DPBS and 
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fixed using 3.7% formaldehyde (Sigma-Aldrich, Dorset, UK) for 10 min at room temperature (RT). 
After fixation, cells were washed with DPBS and permeabilized with 0.2% Triton-X (Sigma-
Aldrich, Dorset, UK) for a further 10 min at RT. Then, the immunostaining blocking was performed 
using 5% bovine serum albumin (BSA) (Sigma-Aldrich, Dorset, UK), to prevent unspecific 
antibody binding. After 1 h at RT, cells were incubated with NF-κB p65 Antibody(F-6) Alexa 
Fluor®647 (Santa Cruz Biotechnology Inc., Heidelberg, Germany) diluted in 1% BSA overnight 
in a humidified chamber at 4 ◦C. The following day, cells were washed with DPBS and the nucleus 
was stained with Hoescht 33342 (Sigma-Aldrich, Dorset, UK) for 10 min at RT before CLSM 
imaging. At least 10 different regions of the petri dishes were acquired and the NF-κB nuclear 
translocation analysis was evaluated by co-localization quantification (Pearson's correlation 
coefficient) of the NF-κB and nucleus fluorescence intensity signals using Fiji ImageJ software 
(version 2.0). 
For assessing the endocytic pathways of polymersomes, THP-1 cells have been incubated with 
Cy5-PMPC-PDPA polymersomes for 30 minutes. After 3 washing steps with PBS, cells have been 
fixed with formaldehyde (3.7%) for 10 minutes, washed again with PBS 3 times, blocked with 5% 
BSA for 1 hour at room temperature and incubated with anti-EEA1 antibody (PA1-0639 EEA1 
Invitrogen) in 1% BSA overnight at 4 °C. Cells were then washed 3 times in PBS/Tween20 (0.02%) 
and incubated with fluorescently labeled secondary antibody for 1 hour at room temperature before 
confocal imaging. For analyzing the co-localization with acidic compartments, cells have been 
inoculated with polymersomes for 30 minutes, washed 3 times with PBS and inoculated with 
LysoTracker™ Green DND-26 (ThermoFisher) according to the manufacturer instruction. 
 
In vivo uptake in zebrafish macrophages. 
- For images in Fig 3. We used either zebrafish larvae with fluorescent macrophages 
Tg(mpeg1:mcherry) of fluorescent vasculature Tg(fli1a:EGFP). General maintenance of zebrafish 
and performance of injection was performed as described in (Fenaroli et al 2018). For blood infection 
experiments: at day 2 post fertilization we injected in the posterior cardinal vein 200 CFU of GFP 
expressing M. marinum. One day later 5 nanoliters of Cy5 labelled PMPC-PDPA polymersomes were 
injected via the posterior cardinal vein. The imaging was performed using an Andor Dragonfly 
spinning disc confocal microscope, using a 10X Plan Apo lens (0.45 NA) for imaging the whole 
embryos (images were stitched together) or a 20X plan Apo len 0.75 NA for imaging the caudal 
region. For macrophage uptake score a confocal stack of the tail region of zebrafish embryos having 
red fluorescent macrophages has been acquired at different time points after injection of Cy5 labelled 
polymersomes. The maximum intensity signal of the nanoparticles and macrophages were 
thresholder and overlapped; the fluorescence intensity of polymersomes within macrophages was 
then scored using the program ImageJ. Normalization of the obtained intensity was performed 
dividing each obtained value by the overall polymersomes fluorescence in the zebrafish embryo. This 
was done by acquiring an image of the whole zebrafish using a Leica DFC365FX stereomicroscope 
with a 1.0× Plan Apo lens at the magnification of 30×. The scoring of the overall fluorescence in the 
embryo was performed using the program Fiji. The normalized values were then multiplied by 1000. 
The macrophage uptake score formula used for quantification is: 
Macrophage uptake score at each time point (5 min, 1h, 8h, 24h) = 
 𝑃𝑜𝑙𝑦𝑚𝑒𝑟𝑜𝑠𝑜𝑚𝑒𝑠𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒𝑖𝑛𝑚𝑎𝑐𝑟𝑜𝑝ℎ𝑎𝑔𝑒𝑠𝑖𝑛𝑡ℎ𝑒𝑡𝑎𝑖𝑙𝑟𝑒𝑔𝑖𝑜𝑛𝑇𝑜𝑡𝑎𝑙𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝑜𝑠𝑜𝑚𝑒𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑋1000 
 
For neural tube infection experiments: at day 3 post fertilization we injected, in the neural tube of 
zebrafish embryos with fluorescent vasculature, 200 CFU of DsRed expressing M. marinum. Four 
days later we injected 5 nanoliters of Cy5 labelled polymersomes. After 8 hours, images of the whole 
zebrafish were taken with an Andor Drangonfly Spinning disc confocal using a 10X Plan Apo lens 
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(0.45 NA); the images were stitched together. For imaging the granuloma areas, a 20X Plan Apo lens 
(0.75 NA) was used.  
For quantification of accumulation of polymersomes in the granuloma area: images of neural tube 
infected zebrafish embryos were taken at different times after the intravenous injection of 5 nL of 
Cy5 labelled polymersomes. For this analysis we used a Leica DFC365FX stereomicroscope with a 
1.0× Plan Apo lens at the magnification of 30×. Using the program ImageJ, the relative fluorescence 
of the polymersomes in the granuloma region or in an uninfected region were scored using a rectangle 
tool of the same size. The value of the uninfected region was considered the background and 
subtracted from the value in granulomas. This resulting value was normalized by the overall 
fluorescence of polymersomes in the zebrafish embryo. The final value was multiplied by 100. The 
formula is then as follows: 
Accumulation in granulomas at each time point (5 min, 1h, 8h, 24h) = 
 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒𝑖𝑛𝑔𝑟𝑎𝑛𝑢𝑙𝑜𝑚𝑎−𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒𝑖𝑛𝑈𝑛𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑𝑎𝑟𝑒𝑎𝑇𝑜𝑡𝑎𝑙𝑧𝑒𝑏𝑟𝑎𝑓𝑖𝑠ℎ𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒  X 100 
 
For Spinning disc confocal microscopy: Anesthetized zebrafish larvae were put on a glass-bottom 
dish (MatTek) and embedded with a solution of low melting point agarose (Sigma). After 
solidification of the solution, embryo water supplemented with tricaine was added to the dish. 
For Leica Stereomicroscope imaging: Anesthetized zebrafish larvae were imaged on a dish having a 
layer of hardened Agarose 2% in water. 
Videos: The videos were made using the program IMARIS; for Supporting video 1 iso surfaces were 
employed to facilitate the view of polymersomes within macrophages.  
 
- For supplementary images. Adult zebrafish were maintained according to standard 
procedures. All experiments were performed on embryos 5 days post fertilization (d.p.f.) or under. 
Transgenic strains used were the Tg(mpx:GFP)i114,43 and the Tg(fms:GFP)sh377.56 In zebrafish 
S. aureus imaging experiments, 2 d.p.f LWT zebrafish embryos were injected with 1200 CFUs of 
CFP-labelled S. aureus followed by an injection of 10 mg/mL rhodamine labelled polymersomes 1 
hour later (10% Rhodamine- PMPC-PDPA, 90% PMPC-PDPA). Zebrafish were incubated for 2 
hours at 28 °C before analysis by fluorescence microscopy using a pSMT3-mCrimson vector or 
pSMT3-mCherry vector.46 Tuberculous granuloma formation is enhanced by a mycobacterium 
virulence determinant. Liquid cultures were prepared from bacterial plates with 50 ฀g/mL 
hygromycin as previously described.46 Specificity of the zebrafish host transcriptome response to 
acute and chronic mycobacterial infection and the role of innate and adaptive immune 
components.57 Injection inoculum was prepared from overnight liquid cultures with an OD600 of 
1, after washing in PBS/Tween 80, and resuspending in 2% polyvinylpyrrolidone40 (PVP40)/PBS. 
Injection of M. marinum into zebrafish embryos was performed into the blood forming region of 
the caudal vein at 28-30 h.p.if. Here 200 CFU, in a volume of 1 nL, were injected. 1 d.p.i., 3 nL of 
Rhodamine labeled polymersomes was injected into the circulation via the Duct of Cuvier. Once 
injected, the embryos were mounted in 1% low melting point agarose and fluorescent confocal 
images and time lapses were generated using a Leica TCS SPE-II microscope using a 40x objective 
(water immersion, HCX PL APO, 1.10NA). 
 
 
In vitro and in vivo quantification of bacterial burden. THP-1 cells were differentiated to 
macrophages in a 96-well plate as previously described. Then we carried out infection with BCG, 
and M. tuberculosis with a Multiplicity of Infection (M.O.I.) of 10:1 for 24 hours, using antibiotics 
free RPMI medium. Cells were then washed 3 times in PBS to remove the excess of 
microorganisms, and incubated with RPMI medium (CTRL), empty polymersomes (CTRL -), 
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polymersomes encapsulated with Rifampicin, Isoniazid, or combination of both, and free 
Rifampicin, Isoniazid, or combination of both free drugs (the antibiotics were all at the same final 
concentration of 1฀g/mL). We tested all these formulations for 24 and 72 hours, then macrophages 
were lysed with 0.05% SDS, and the CFUs quantified with the SPOTi assay. We carried out serial 
dilutions of each lysis solution, and 10 ฀L of them were aliquoted on Middelbrock 7H11 agar 
medium for a period of 25-30 days, or until some colonies were visible. Colony counting was 
carried out manually. For THP-1 S. aureus experiments, mid-log S. aureus (Newman strain), were 
centrifuged at 10,000G for 1 minute and resuspended in 1 mL PBS. 106 CFUs were added to each 
well (MOI of 5:1). The cells were then placed on ice for 1 hour followed by a further 5 hours in a 
37°C incubator (total 6 hours incubation). After incubation, gentamicin was added to the media 
(150 ฀g/mL) and the cells were left for 30 minutes in an incubator to kill the extracellular bacteria. 
The samples were removed from the incubator, washed twice with PBS and then replaced with 
RPMI media containing 15 ฀g/mL of gentamicin and the treatment or control was added. At each 
specified time point (6.5 hours, 22 hours, and 48 hours post infection) the media was removed, the 
cells were washed twice with PBS and then 250 ฀L of 1% Saponin (Sigma Aldrich) was added to 
lyse the cells. The macrophages were left in the Saponin for 12 minutes in a 37°C incubator and 
then an additional 750 ฀L of PBS was added to the cells and the wells were mixed thoroughly with 
a pipette. 10 ฀L of the lysed cells were taken and diluted in a 96 well plate with six 1/10 serial 
dilutions. Three 10 ฀L drops from each dilution were placed onto a labelled blood agar plate, 
incubated overnight at 37°C and the number of viable colonies were counted. For zebrafish in vivo 
S. aureus experiments, 2 d.p.if. LWT zebrafish were injected with 1200 CFUs of GFP-labelled S. 
aureus. 18 hours after injection zebrafish were viewed under a fluorescent dissecting microscope 
(Leica MZ10F) and zebrafish with visible abscesses were discarded. 20 hours post infection, 
zebrafish were injected with 0.5 nL of 1mg/mL polymersomes with 37.5 ฀g/mL of encapsulated 
rifampicin or their subsequent controls. Zebrafish embryos were incubated at 28°C for a further 20 
hours following polymersomes injections and were then homogenized using the PreCellys 24-Dual 
(Peqlab). The homogenates were serially diluted onto BHI agar plates, placed 
in a 37°C room and the number of viable colonies was manually counted the following morning. 
In order to quantify the in vivo microorganism burden, injection of M. marinum into zebrafish 
embryos was performed into the blood forming region of the caudal vein at 28-30 h.p.f. 100 CFU, 
in a volume of 3 nL, were injected. 1 d.p.i., 1 nL of PBS (Ctrl), empty polymersomes, free 
Rifampicin (3.6 mM) or Rifampicin-encapsulated polymersomes (3.6 mM) were injected into the 
circulation via the Duct of Cuvier. Embryos were imaged at 4 d.p.i. on a wide field Leica DMi8 
using a 2.5x objective (air, HC FL PLAN, 0.07NA) with images generated with a Hamamatsu Orca 
Flash 4.0 V2 camera. Bacterial burden was analyzed suing pixel counting software as previously 
described.34 Data were analyzed using one-way ANOVA (with Bonferroni post-test adjustment) in 
Prism 6.0 software (GraphPad Software, Sand Diego, CA, USA). 
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